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Abstract: Drug abuse is considered as the most common poisoning in the world. Stimulants agent especially am-
phetamines and methamphetamines are among important abused substances. Different types of neurologic,
psychiatric, respiratory, gastrointestinal, and cardiogenic complications have been reported to be related to
methamphetamine consumption. Some of these substances could cause dysrhythmias which is the most preva-
lent etiology of cardiogenic syncope. Ecstasy, as one of the most commonly abused drugs, is known as a cause
of cardiac dysrhythmias. Here we report a young boy who was admitted into the emergency department follow-
ing three syncope attacks. All cardiac and neurologic assessments were normal; and finally ecstasy abuse was
detected as the main etiology of syncopes.
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1. Introduction
Drug abuse is considered as the most common poisoning
in the world and about 2 to 5 million of such poisoning oc-
cur annually in the united states (1). Stimulants agent es-
pecially amphetamines and methamphetamines are among
important abused substances (2). Different types of neu-
rologic, psychiatric, respiratory, gastrointestinal, and car-
diogenic complications have been reported to be related to
methamphetamine consumption (3-7). Some of these sub-
stances could cause dysrhythmias which is the most preva-
lent etiology of cardiogenic syncope (8). To emphasize the
importance of this topic, here we report a case of recurrent
syncope following amphetamine abuse.
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2. Case presentation:
An 18-year-old boy was admitted to the emergency depart-
ment of Markaze–Tebi–Koodakan Hospital, Tehran, Iran with
chief complaint of sudden weakness, transient loss of con-
sciousness and falling down at home. A meticulous history
of the patient revealed 2 similar attacks in last 3 months. Fur-
ther evaluations in previous attacks including brain imaging,
cardiac stress test were all negative and genetic testing re-
vealed no evidence of channelopathies. There was no history
of head trauma, cardiac disease or regular medication use.
The patient denied any substance abuse and family history
revealed no sudden cardiac death. The patient’s vital signs
on admission were stable, neurological and cardiac exami-
nations were normal. His Glasgow coma score (GCS) was
15/15, pupils responded normally to light, deep tendon re-
flex (DTR) and cranial nerves examinations did not revealed
any abnormality. Electrolytes, blood sugar level, and thy-
roid function tests were performed and all were reported in
normal range. The patient’s electrocardiogram (ECG) on ar-
rival was normal. Echocardiographic evaluation showed no
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Figure 1: 24 hours cardiac holter monitoring. a uniform, sustained
ventricular tachycardia.
structural heart disease. Brain magnetic resonance imaging
(MRI) and electroencephalography (EEG) were normal and
the tilt test result was negative. Twenty-four hour cardiac
holter monitoring was performed in which a uniform, sus-
tained ventricular tachycardia (VT) was revealed (Figure 1).
Psychiatric consultation was carried out due to poor family
support and chaotic family interactions. Psychiatric consul-
tation revealed that the patient had two previous suicide at-
tempts and history of ecstasy abuse. Based on history, he
had used ecstasy a night before, thereby resulting in syn-
cope attacks. An evaluation of serum toxins level revealed a
methamphetamine serum level of 12 mg/dl. The patient was
discharged with a diagnosis of syncope caused by VT due to
methamphetamine abuse. Psychiatric follow-up was advised
for 6 months. During this period, ecstasy usage was discon-
tinued and he did not experience any episode of syncope at-
tacks.
3. Discussion:
Although, intoxication and their complications are usually
associated with overdose consumption of abuse drugs, but
the use of actual dose of amphetamine may lead to car-
diovascular events (9). Palpitation, premature ventricu-
lar and supraventricular contraction, accelerated atrioven-
tricular conduction, atrioventricular block, bundle branch
block, supraventricular tachycardia, ventricular tachycardia
and fibrillation are among the most prevalent cardiogenic
complications (10). In a study by Fabrizio et al. it was
shown that methylenedioymethamphetamine (MDMA) in-
duces arrhythmia through the release of serotonin and cat-
echolamine (especially noradrenaline), which are responsi-
ble for most severe accidents in the cardiovascular system
(4). Elevated catecholamine level causes tachycardia and hy-
pertension that lead to increased oxygen demand and va-
sospasm. Myocardial ischemia occurs in response to de-
creasing oxygen supply and increasing oxygen demand in the
myocardium that leads to increasing the potential risk of car-
diac arrhythmia (11). Zhuo et al. demonstrated the mecha-
nism of reduction of connexin 43 and N-cadherin (myocar-
dial gap junction proteins) in the pathophysiology of car-
diovascular arrhythmia due to MDMA exposure. MDMA re-
duces both connex in 43 and N-cadherin. These forms of
proteins are multiprotein complexes that could allow the as-
semblage of both gap and fascia adherens junctions. Loss
or decreased gap junction-proteins may disrupt cardiac im-
pulse propagation and result in ventricular arrhythmia (12).
After cannabis, methamphetamines and their compounds
have become the most widely abused illicit drugs all over
the world (8, 13). Ecstasy is an easily available drug and
used mainly by young individuals in parties. This case study
presents a young man with recurrent syncope further diag-
nosed as ecstasy abuse as the main cause. In syncope with
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